Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 16January 2023 – On 4 November 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.
Under the programme initiated 4 November 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 7 November 2022 to 30 January 2023.
Since the announcement of the programme, the following transactions have been made:
| Number of B shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 3,050,265 | 2,684,398,099 | |
| 9 January 2023 | 74,000 | 964.21 | 71,351,652 |
| 10 January 2023 | 80,000 | 932.47 | 74,597,253 |
| 11 January 2023 | 80,000 | 915.51 | 73,241,142 |
| 12 January 2023 | 80,000 | 908.42 | 72,673,892 |
| 13 January 2023 | 75,000 | 931.50 | 69,862,150 |
| Accumulated under the programme | 3,439,265 | 3,046,124,188 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 30,868,083 B shares of DKK 0.20 as treasury shares, corresponding to 1.4% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 13 January 2023, Novo Nordisk has since 2 February 2022 repurchased a total of 29,178,897 B shares at an average share price of DKK 796.11 per B share equal to a transaction value of DKK 23,229,526,243.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 53,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn andYouTube.
Contact for further information
| Media: | |
| Ambre Brown Morley +45 3079 9289 abmo@novonordisk.com | Natalia SalomaoAbrahao (US) +1 848 304 1027 niaa@novonordisk.com |
| Investors: | |
| Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com | Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
| David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
Company announcement No 02 / 2023
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Shareholders approve all resolutions on the agendas of Tenaris’s Annual General Meeting and Extraordinary General Meeting of Shareholders1.5.2024 23:10:26 CEST | Press release
LUXEMBOURG, May 01, 2024 (GLOBE NEWSWIRE) -- Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced that its annual general meeting of shareholders and its extraordinary general meeting of shareholders, both held on April 30, 2024, approved all resolutions on their agendas. Among other resolutions adopted at the annual general meeting, shareholders acknowledged the Company’s 2023 annual report, containing the consolidated management report and the related management certifications and external auditors’ reports, and the Company’s 2023 annual sustainability report, containing the non-financial statement required by Luxembourg law. The shareholders also approved the consolidated financial statements as of and for the year ended December 31, 2023, and the annual accounts as at December 31, 2023. The annual general meeting also approved an annual dividend of US$0.60 per share (or US$1.20 per ADR), which represents an aggregate sum of approximately US$0.7 billion, and which include
CNH is changing its NYSE ticker symbol to “CNH” on May 201.5.2024 22:30:00 CEST | Press release
Basildon, May 1, 2024 CNH Industrial (NYSE: CNHI) announces that the Company’s common shares listed on the New York Stock Exchange (NYSE) will begin trading under the symbol “CNH” effective Monday, May 20, 2024. This will replace the Company’s current ticker symbol, “CNHI”, marking a return to both our original ticker symbol “CNH” – used until 2013 – and our identity as a leading pureplay provider of equipment, technology and services for agriculture and construction. CNH Industrial N.V. will remain the name of the legal entity. The ticker symbol for the Company’s 3.850% Notes due 2027 will also change from “CNHI 27” to “CNH 27” at the same time. No action is required by the Company's shareholders or bondholders with respect to the ticker symbol changes, as the Company’s common stock and notes will continue to be listed on the NYSE and their CUSIP numbers will remain unchanged. CNH Industrial (NYSE: CNHI) is a world-class equipment and services company. Driven by its purpose of Breakin
Koelis Announces New Product Release at AUA 2024 to Offer Innovative AI-Enhanced MRI Fusion Biopsy Workflow1.5.2024 20:48:50 CEST | Press release
GRENOBLE, France and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in prostate care, announced today the release of new features at the prestigious American Urological Association Annual Meeting in San Antonio, TX. Koelis will be holding live and interactive demos at its booth #951 from May 2nd to May 5th to demonstrate its novel capacity integrating AI-enhanced prostate MRI features into its exclusive Trinity platform. The Koelis Trinity® system enables urologists to perform 3D targeted “fusion biopsy” in prostate cancer. Trinity integrates 3D ultrasound imaging with proprietary MRI-US fusion image guidance that features the Company’s unique prostate motion tracking software (OBT Fusion®). The compact Koelis Trinity® system does not require interfaces with either external ultrasound equipment or external sensors. The versatility of the Trinity platform is enabling Koelis to lead the ongoing paradigm sh
Awilco Drilling Plc: Keppel denied leave to appeal the ruling of the AR2 arbitration tribunal1.5.2024 20:34:14 CEST | Press release
Further to the stock exchange releases of 23 November 2023 and 15 January 2024 from Awilco Drilling PLC ("Awilco Drilling") regarding the termination of the newbuilding contract between Awilco Rig 2 Pte. Ltd. ("AR2") and Keppel FELS Limited ("KFELS") for the construction of a semi-submersible drilling rig, hull number B382. The Company has today received the decision of the High Court refusing Keppel’s application for leave to appeal the award of the AR2 arbitration tribunal. The award is in AR2's favour in an amount of USD 43.0 million plus interest and legal costs. Unless the parties can mutually agree, the tribunal will issue a further award related to interest and costs. We will revert once the award has been received and the amounts of interest and costs have been determined. Aberdeen, 1 May 2024 For further information please contact: Eric Jacobs, CEO of Awilco Drilling PLC Phone: +47 9529 2271 Cathrine Haavind, Investor Relations of Awilco Drilling PLC Phone: +47 9342 8464 Email
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond1.5.2024 18:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8’000’000 Idorsia shares. All other matters as proposed on April 23, 2024, remain unchanged.The bondholder meeting will take place on May 6, 2024, in order to vote on the proposals published on April 23, 2024. Allschwil, Switzerland – May 1, 2024 Idorsia Ltd (SIX: IDIA) today announced that in relation to the bondholder meeting for holders of its outstanding convertible bonds maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds), Idorsia has improved the consent fee to 8’000’000 Idorsia shares up from 5’000’000. Other elements of the proposal published on April 23, 2024 such as the (i) amendment to the conversion price to CHF 6.00 (from currently CHF 33.95), (ii) extension of the maturity date by six months to January 17, 2025 and (iii) giving Idorsia the option to call the Bonds at par, in full or in part, at any time upon giving ten trading days' notice, remain unchanged. Bondholders can acc